Amesika Nyaku

Dr. Amesika Nyaku

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2017 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
BTBabafemi O Taiwo
Babafemi O Taiwo
LZLu Zheng
Lu Zheng
ASAndrei Stefanescu
Andrei Stefanescu
ANAmesika Nyaku
Amesika Nyaku
BBBaiba Bezins
Baiba Bezins
RGRoy M Gulick
Roy M Gulick
Limited data exist on initial human immunodeficiency virus type 1 (HIV-1) treatment with dolutegravir plus lamivudine. A5353 is a phase 2, single-arm, pilot study of once-daily dolutegravir (50 mg) plus lamivudine (300 mg) in treatment-naive participants with HIV-1 RNA ≥1000 and <500000 copies/mL. Exclusion criteria included active hepatitis B or major protease, reverse transcriptase, or integrase resistance. The primary efficacy measure was the proportion with HIV-1 RNA 400 copies/mL at week 16/20 or >200 copies/mL at or after week 24. Dolutegravir levels and drug resistance testing were performed at VF. One hundred and twenty participants (87% male, median age 30 years, 37 (31%) HIV-1 RNA >100000 copies/mL) initiated study treatment. Median entry HIV-1 RNA and CD4 count were 4.61 log10 copies/mL and 387 cells/mm3. Virologic efficacy at week 24 was 108/120 (90%, confidence interval [83%, 95%]), with comparable results in the >100000 copies/mL and ≤100000 copies/mL strata, that is, 89% (75%, 97%) and 90% (82%, 96%), respectively. Three participants with VF, had undetected plasma dolutegravir at ≥1 time points; the M184V and R263R/K mutations developed in 1 participant. Two participants experienced grade 3 possible/probable treatment-related adverse events; none discontinued treatment due to adverse events. Dolutegravir plus lamivudine demonstrated efficacy in individuals with pretreatment HIV-1 RNA up to 500000 copies/mL in this pilot trial, but a participant developed resistance mutations. NCT02582684.

21 December 2017 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
BTBabafemi O Taiwo
Babafemi O Taiwo
VMVincent C Marconi
Vincent C Marconi
BBBaiba Berzins
Baiba Berzins
CMCarlee B Moser
Carlee B Moser
ANAmesika Nyaku
Amesika Nyaku
PSPaul E Sax
Paul E Sax
In this randomized pilot clinical trial, dolutegravir plus lamivudine was noninferior to continuation of standard 3-drug maintenance antiretroviral therapy. There was no emergence of drug resistance in the participant who experienced virologic failure while receiving dolutegravir plus lamivudine.

1 January 2022 in Journal of Substance Abuse Treatment
Verified
Journal Article
Closed access
PTPeter C. Treitler
Peter C. Treitler
CBCadence F. Bowden
Cadence F. Bowden
JLJames Lloyd
James Lloyd
MEMichael Enich
Michael Enich
ANAmesika Nyaku
Amesika Nyaku
SCStephen Crystal
Stephen Crystal

16 March 2017 in Current HIV/AIDS Reports
Verified
Journal Article
Closed access
PDF file
ANAmesika Nyaku
Amesika Nyaku
SKSean G Kelly
Sean G Kelly
BTBabafemi O Taiwo
Babafemi O Taiwo

17 February 2016 in Drugs
Verified
Journal Article
Closed access
PDF file
SKSean G. Kelly
Sean G. Kelly
ANAmesika Nyaku
Amesika Nyaku
BTBabafemi O. Taiwo
Babafemi O. Taiwo

11 February 2019 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
JLJonathan Z Li
Jonathan Z Li
PSPaul E Sax
Paul E Sax
VMVincent C Marconi
Vincent C Marconi
JFJesse Fajnzylber
Jesse Fajnzylber
BBBaiba Berzins
Baiba Berzins
BTBabafemi O Taiwo
Babafemi O Taiwo
In the ASPIRE trial, antiretroviral therapy (ART) switch to dolutegravir plus lamivudine (DTG+3TC) was comparable to 3-drug ART in maintaining viral suppression by standard viral load assays. We used an ultrasensitive assay to assess whether this switch led to increased residual viremia. At entry, levels of residual viremia did not differ significantly between arms (DTG+3TC vs 3-drug ART: mean, 5.0 vs 4.2 HIV-1 RNA copies/mL; P = .64). After randomization, no significant between-group differences were found at either week 24 or 48. These results show no evidence for increased viral replication on DTG+3TC and support its further investigation as a dual ART strategy.